Qiaosi Tang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Qiaosi Tang has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Andres J. Klein-Szanto
Histopathology Facility, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
43 shared publications - Anil K. Rustgi
Columbia University Irving Medical Center 3 Division of Digestive and Liver Diseases, Department of Medicine, Vagelos College of Physicians and Surgeons New York, New York
43 shared publications - Gizem Efe
Vagelos College of Physicians and Surgeons, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York 10032, USA
43 shared publications - Karen J. Dunbar
Herbert Irving Comprehensive Cancer Center, New York, NY, 10032, USA
43 shared publications - Brian S. Henick
Columbia University Irving Medical Center, New York, NY
40 shared publications - Eric W. Lin
Mass General Cancer Center, Harvard Medical School, Charlestown, Massachusetts
40 shared publications
Latest Publications
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure Legends from Tumor-Derived CCL5 Recruits Cancer-Associated Fibroblasts and Promotes Tumor Cell Proliferation in Esophageal Squamous Cell Carcinoma
Supplementary Figure Legends 1-4
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure Legends from Tumor-Derived CCL5 Recruits Cancer-Associated Fibroblasts and Promotes Tumor Cell Proliferation in Esophageal Squamous Cell Carcinoma
Supplementary Figure Legends 1-4
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Tumor-Derived CCL5 Recruits Cancer-Associated Fibroblasts and Promotes Tumor Cell Proliferation in Esophageal Squamous Cell Carcinoma
ERK1/2 signaling pathway in CCL5 knockout cells.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Tumor-Derived CCL5 Recruits Cancer-Associated Fibroblasts and Promotes Tumor Cell Proliferation in Esophageal Squamous Cell Carcinoma
ERK1/2 signaling pathway in CCL5 knockout cells.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Tumor-Derived CCL5 Recruits Cancer-Associated Fibroblasts and Promotes Tumor Cell Proliferation in Esophageal Squamous Cell Carcinoma
Loss of tumor-derived CCL5 reduces tumor cell proliferation in TE-1 cells.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Tumor-Derived CCL5 Recruits Cancer-Associated Fibroblasts and Promotes Tumor Cell Proliferation in Esophageal Squamous Cell Carcinoma
Loss of tumor-derived CCL5 reduces tumor cell proliferation in TE-1 cells.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Tumor-Derived CCL5 Recruits Cancer-Associated Fibroblasts and Promotes Tumor Cell Proliferation in Esophageal Squamous Cell Carcinoma
Targeted CCR5 inhibition replicates CCL5 loss with reduced tumor cell proliferation in vitro and in vivo.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Tumor-Derived CCL5 Recruits Cancer-Associated Fibroblasts and Promotes Tumor Cell Proliferation in Esophageal Squamous Cell Carcinoma
Targeted CCR5 inhibition replicates CCL5 loss with reduced tumor cell proliferation in vitro and in vivo.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Tumor-Derived CCL5 Recruits Cancer-Associated Fibroblasts and Promotes Tumor Cell Proliferation in Esophageal Squamous Cell Carcinoma
Confirmation of CCL5 knockout clones.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Tumor-Derived CCL5 Recruits Cancer-Associated Fibroblasts and Promotes Tumor Cell Proliferation in Esophageal Squamous Cell Carcinoma
Confirmation of CCL5 knockout clones.
- Open Access
MGMG: Cell Morphology-Guided Molecule Generation for Drug Discovery
Designing novel molecules with desired bioactivity remains a fundamental challenge in drug discovery. Most molecular design methods follow target-based drug discovery paradigms that rely on well-defined drug targets, thereby limiting their applicability to diseases lacking known targets or reference compounds. Here we introduce Morphology-Guided Molecule Generation (MGMG), a phenotypic drug discovery–oriented approach that integrates cellular morphological profiles from compound treatments with molecular textual descriptions without requiring molecular target information. Cell morphology offers the guidance on desired bioactivity-relevant phenotypic effects, while textual descriptions provide direct and interpretable cues about molecular structure. Leveraging complementary structural and bioactivity context, MGMG significantly enhances molecule generation performance, especially in scenarios where textual descriptions are under-informative or morphological signals are weak. MGMG can also be applied to genetic perturbations, enabling activator design from gene overexpression morphology without requiring knowledge of reference compound structure. In addition, in silico docking demonstrates that MGMG-generated molecules, despite lacking target information, exhibit binding affinities comparable to reference compounds, preserving key interactions while introducing structural diversity. Overall, MGMG jointly utilizes morphological and textual description inputs to guide molecule generation, enabling diverse, bioactivity-aware compound design in a target-agnostic fashion.
Open AccessMGMG: Cell Morphology-Guided Molecule Generation for Drug Discovery
Designing novel molecules with desired bioactivity remains a fundamental challenge in drug discovery. Most molecular design methods follow target-based drug discovery paradigms that rely on well-defined drug targets, thereby limiting their applicability to diseases lacking known targets or reference compounds. Here we introduce Morphology-Guided Molecule Generation (MGMG), a phenotypic drug discovery–oriented approach that integrates cellular morphological profiles from compound treatments with molecular textual descriptions without requiring molecular target information. Cell morphology offers the guidance on desired bioactivity-relevant phenotypic effects, while textual descriptions provide direct and interpretable cues about molecular structure. Leveraging complementary structural and bioactivity context, MGMG significantly enhances molecule generation performance, especially in scenarios where textual descriptions are under-informative or morphological signals are weak. MGMG can also be applied to genetic perturbations, enabling activator design from gene overexpression morphology without requiring knowledge of reference compound structure. In addition, in silico docking demonstrates that MGMG-generated molecules, despite lacking target information, exhibit binding affinities comparable to reference compounds, preserving key interactions while introducing structural diversity. Overall, MGMG jointly utilizes morphological and textual description inputs to guide molecule generation, enabling diverse, bioactivity-aware compound design in a target-agnostic fashion.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Tumor-derived CCL5 recruits cancer-associated fibroblasts and promotes tumor cell proliferation in esophageal squamous cell carcinoma
Confirmation of CCL5 knockout clones.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Tumor-derived CCL5 recruits cancer-associated fibroblasts and promotes tumor cell proliferation in esophageal squamous cell carcinoma
Confirmation of CCL5 knockout clones.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Tumor-derived CCL5 recruits cancer-associated fibroblasts and promotes tumor cell proliferation in esophageal squamous cell carcinoma
Targeted CCR5 inhibition replicates CCL5 loss with reduced tumor cell proliferation in vitro and in vivo.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Tumor-derived CCL5 recruits cancer-associated fibroblasts and promotes tumor cell proliferation in esophageal squamous cell carcinoma
Targeted CCR5 inhibition replicates CCL5 loss with reduced tumor cell proliferation in vitro and in vivo.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure Legends from Tumor-derived CCL5 recruits cancer-associated fibroblasts and promotes tumor cell proliferation in esophageal squamous cell carcinoma
Supplementary Figure Legends 1-4
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure Legends from Tumor-derived CCL5 recruits cancer-associated fibroblasts and promotes tumor cell proliferation in esophageal squamous cell carcinoma
Supplementary Figure Legends 1-4
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Tumor-derived CCL5 recruits cancer-associated fibroblasts and promotes tumor cell proliferation in esophageal squamous cell carcinoma
ERK1/2 signaling pathway in CCL5 knockout cells.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Tumor-derived CCL5 recruits cancer-associated fibroblasts and promotes tumor cell proliferation in esophageal squamous cell carcinoma
ERK1/2 signaling pathway in CCL5 knockout cells.